Abbott Korea gets approval for additional indication of Humira

Published: 2012-08-16 06:59:00

Updated: 2012-08-16 06:59:00

Abbott Korea announced Monday that they have received approval from the Korea Food and Drug Administration for treatment of moderate to severe ulcerative colitis (UC) as an additional indication of Humira (adalimumab).

The approval came after the KFDA analyzed the clinical results of adult pat...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK